Company intelligence / Profile preview

Inhibitor Therapeutics, Inc.

Tampa, Florida, United Statesinhibitortx.com ↗

Ownership: Public · INTI
Employees: ~9
Development stage: Phase 2

Overview

The company’s lead candidate SUBA-Itraconazole has completed a positive Phase 2b trial in basal cell carcinoma nevus syndrome. Itraconazole has shown activity against multiple tumor types and the company holds significant IP around its use in oncology. Other programs are at earlier stages targeting prostate and lung cancers using repurposed small molecules.

Therapeutic areas: OtherOncology
Modalities: Small molecules (repurposed drugs; specifically oral itraconazole)
Industry: Biotech

Drug pipeline

1 asset

ITZ analogue

Preclinical

Partnerships

Johns Hopkins University (license agreement)

Financials

Market cap: $15M
Total revenue: $0
Enterprise value: $14.5M

Beyond the preview

Go deeper on Inhibitor Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inhibitor Therapeutics, Inc..

Explore the full profile